Soll Eye Associates Report issue

Academic/Hospital Phase 1 Phase 4

Organization Overview

First Clinical Trial
2008
NCT00595543
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Alternative names

Soll Eye

Active Ingredients

Drugs in Phase 4 Trials (3)

bromfenac (xibrom) (1 trial)

diclofenac (voltaren) (1 trial)

ketorolac (acuvail) (1 trial)

Drugs in Phase 1 Trials (2)

ranibizumab (lucentis) (1 trial)

triamcinolone (kenalog) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Edema (Phase 4)

Macular Edema (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 5